Geron (GERN) Capital Expenditures (2010 - 2024)
Geron's (GERN) quarterly Capital Expenditures came in at -$141000.0 in Q4 2024, down 320.31% year-over-year from $64000.0 in Q1 2024, and down 7150.0% quarter-over-quarter from $2000.0 in Q2 2024.
Analysis
Geron (GERN) Capital Expenditures (2010 - 2024) Analysis & Trends
Geron has disclosed Capital Expenditures across 15 years of filings, most recently posting -$141000.0 for Q4 2024.
- In Q4 2024, Capital Expenditures fell 320.31% year-over-year to -$141000.0; the TTM figure through Dec 2024 stood at $680000.0 (down 18.07% YoY), while the FY2024 annual figure was $680000.0, down 18.07% from the prior year.
- Capital Expenditures came in at -$141000.0 for Q4 2024 at Geron, down from $2000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $19.0 million in Q3 2022 to a low of -$24.1 million in Q4 2022.
- Average Capital Expenditures over 5 years is $134157.9, with a median of $2000.0 recorded in 2024.
- The largest YoY upside for Capital Expenditures was 5818.69% in 2022 against a maximum downside of 662.83% in 2022.
- Over 5 years, Capital Expenditures stood at -$2.2 million in 2020, then sank by 45.98% to -$3.2 million in 2021, then slumped by 662.83% to -$24.1 million in 2022, then surged by 100.27% to $64000.0 in 2023, then plunged by 320.31% to -$141000.0 in 2024.
- Per Business Quant data, the three most recent Capital Expenditures figures were -$141000.0 in Q4 2024, $2000.0 in Q2 2024, and $819000.0 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.87 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -141,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 819,000.00 |
| Dec 31, 2023 | 64,000.00 |
| Sep 30, 2023 | 192,000.00 |
| Jun 30, 2023 | 2.49 Mn |
| Mar 31, 2023 | -1.92 Mn |
| Dec 31, 2022 | -24.08 Mn |
| Sep 30, 2022 | 19.00 Mn |
| Jun 30, 2022 | -1.79 Mn |
| Mar 31, 2022 | 7.29 Mn |
| Dec 31, 2021 | -3.16 Mn |
| Sep 30, 2021 | 321,000.00 |
| Jun 30, 2021 | -715,000.00 |
| Mar 31, 2021 | 3.76 Mn |
| Dec 31, 2020 | -2.16 Mn |
| Sep 30, 2020 | 2.95 Mn |
| Jun 30, 2020 | -140,000.00 |
| Mar 31, 2020 | -249,000.00 |
| Dec 31, 2019 | -986,000.00 |